Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Belzutifan + Lenvatinib or Pembrolizumab/Quavonlimab + Lenvatinib vs Pembrolizumab + Lenvatinib in First-Line Advanced ccRCC
NCT04736706Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 35
01
Overview
A Phase 3 trial of belzutifan, pembrolizumab + quavonlimab in clear cell renal cell carcinoma (ccRCC), sponsored by Merck & Co.. Started Apr 2021; status: active, not recruiting.
02
Drugs
belzutifanpembrolizumab + quavonlimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04736706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736706.